DLEU2L

Across TCGA pan-cancer cohorts, DLEU2L RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of DLEU2L’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where DLEU2L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DLEU2L is over-expressed in tumor, although a few such as UCEC show the opposite, repressed pattern.

CHOL, BLCA, and LIHC are the cancer types where DLEU2L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DLEU2L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	All	All	+0.517	<.001	5	view →
BLCA	Female	All	+0.236	.018	5	view →
LIHC	All	All	+0.038	.004	5	view →
KIRC	All	All	+0.098	.005	4	view →
STAD	All	All	+0.147	.031	3	view →
UCEC	All	All	−0.188	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

DLEU2L–CHOL

Open the CHOL breakdown →